Cardiol Therapeutics Inc Class A stock has shown notable performance this week, reflecting its recent developments and market sentiment.
Cardiol Therapeutics Inc Class A (CRDL.TO) has experienced a week of positive price action, increasing by 3.61% over the past week, with a notable year-to-date gain of 89.71%. The stock closed at C$2.76, maintaining steady trading volume that slightly surpassed its 20-day average.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$301.40M
52W high
$2.75
52W low
$1.23
1W change
+3.61%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 132.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+132.6% Upside
Current Price
C$2.58
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
69.1%
Annualized
90-Day Vol
59.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.74 | C$2.16 – C$3.48 |
| 60 trading days | C$2.91 | C$2.07 – C$4.07 |
| 90 trading days | C$3.08 | C$2.04 – C$4.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find Cardiol Therapeutics appealing given its significant year-to-date performance and recent advancements in clinical research, despite the absence of major news this week.
Cardiol Therapeutics Inc Class A Stock Up 3.61% This Week
The stock has gained 54.49% over the past month, reflecting increasing investor interest and potential positive sentiment in the healthcare sector.
Bull case
The company’s recent participation in industry conferences and the publication of positive clinical trial results could boost investor confidence and attract further interest in the stock. These developments suggest that Cardiol Therapeutics is actively working to advance its treatment options, which may resonate well with investors looking for growth potential.
Bear case
Despite its strong performance, the company faces challenges, including a negative return on equity and ongoing financial losses, which could impact future growth potential. These factors may raise concerns among investors about the sustainability of its recent gains and overall financial health.
Recent Price Action
Advertisement
Cardiol Therapeutics Inc Class A (CRDL.TO) has closed at C$2.76, with a 1-day change of 0.00%. Over the past week, the stock has gained 3.61%, and it has surged 54.49% over the last month. Year-to-date, the stock has delivered an impressive return of 89.71%. The trading volume for the latest session was 275,862 shares, representing a slight increase compared to the 20-day average volume of 204,560 shares.
Company News and Developments
While there was no major news from Cardiol Therapeutics this week, the company has recently been involved in significant events. Notably, it participated in a fireside chat at Canaccord Genuity’s 46th Annual Growth Conference, which could provide a platform for discussing its advancements in treatment options. Additionally, data from its Phase II recurrent pericarditis study was published in the Journal of the American Heart Association, highlighting the efficacy of its lead product, CardiolRx™, in managing this condition.
Technical Picture
From a technical standpoint, Cardiol Therapeutics is trading well above its 50-day moving average of C$1.77 (+55.8% vs price) and its 200-day moving average of C$1.60 (+72.2% vs price). The stock is currently positioned within its 52-week range of C$1.23 to C$2.75, sitting at 101% of this range. With a beta of 0.47, the stock demonstrates lower volatility compared to the broader market, which may appeal to risk-averse investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
